Brokerage Firm Rating Update on Laboratory Corporation of America Holdings (LH)

Laboratory Corporation of America Holdings (LH) : 9 brokerage houses believe that Laboratory Corporation of America Holdings (LH) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Laboratory Corporation of America Holdings (LH). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 14 Wall Street Analysts endorse the stock as a Buy with a rating of 1.54.

Laboratory Corporation of America Holdings (LH) stock is expected to deviate a maximum of $9.42 from the average target price of $148.42 for the short term period. 13 Street Experts have initiated coverage on the stock with the most promising target being $160 and the most muted being $132.


For the current week, the company shares have a recommendation consensus of Buy. Also, KeyBanc maintains their rating on the shares of Laboratory Corporation of America Holdings (NYSE:LH). The current rating of the shares is Overweight. Equity Analysts at the Firm raises the price target to $150 per share from $143 per share. The rating by the firm was issued on August 16, 2016.

Laboratory Corporation of America Holdings (NYSE:LH): The stock opened at $138 and touched an intraday high of $140.595 on Wednesday. During the day, the stock corrected to an intraday low of $137.91, however, the bulls stepped in and pushed the price higher to close in the green at $140.46 with a gain of 1.51% for the day. The total traded volume for the day was 820,007. The stock had closed at $138.37 in the previous trading session.

Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Companys non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, womens health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.